Research programme: interleukin-13 antagonists - ASLAN Pharmaceuticals

Drug Profile

Research programme: interleukin-13 antagonists - ASLAN Pharmaceuticals

Alternative Names: ASLAN-004; CSL334; IL-13R; IL-13R - Merck; IL-13Rα1 project; MK 6105; Novel Receptor 4 discovery project; NR4 discovery project

Latest Information Update: 22 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co; Zenyth Therapeutics
  • Developer ASLAN Pharmaceuticals; CSL; Merck & Co
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 13 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 13 May 2014 Discontinued - Preclinical for Asthma in Australia (Parenteral)
  • 11 Oct 2012 Preclinical development is ongoing in Australia
  • 29 Sep 2009 Preclinical development is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top